CAMBRIDGE, Mass. and BOSTON and BERLIN, Jan. 22, 2019 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and ProBioGen, a premier German service and technology provider, today announced a multi-year research collaboration focused on the development of novel in vivo delivery modalities for CRISPR/Cas9 leveraging ProBioGen’s existing technology and expertise.
“Our CRISPR/Cas9 platform has transformative potential across a broad range of devastating, genetically-defined diseases,” said Tony Ho, M.D., Executive Vice President, Research and Development at CRISPR Therapeutics. “To ensure we deliver on this potential, we continue to seek out pioneering new technologies and capabilities in support of our programs. We look forward to working with the ProBioGen team and leveraging their expertise to enhance our research and development efforts on in vivo delivery of CRISPR/Cas9.”
ProBioGen’s Chief Scientific Officer, Dr. Volker Sandig said: “We are glad to embark on a project with CRISPR for the joint development of novel technologies for in vivo delivery of CRISPR/Cas9. This agreement combines the ideas, know-how and experience of both companies, and we look forward to enhancing CRISPR Therapeutics’ highly innovative approach through this collaboration.”
Technical and financial details of the collaboration were not disclosed. The collaboration includes a license option for CRISPR Therapeutics upon successful completion of the research goals.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.
About ProBioGen AG – www.probiogen.de
ProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic glycoproteins. Combining both state-of-the-art development platforms, based on ProBioGen’s CHO.RiGHT® expression and manufacturing platform, together with intelligent product-specific technologies, yields biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA). ProBioGen was founded 1994, is privately owned and located in Berlin, Germany.